Kyron.bio

Kyron.bio is pioneering a new frontier in drug design by engineering therapeutic production cells to precisely control the sugars that coat protein surfaces. These sugar molecules dramatically influence therapeutic function and performance. Kyron.bio’s technology has demonstrated the ability to prevent unwanted immune responses to antibody therapies and enhances the stability and efficacy of protein-based drugs used in treating cancer, autoimmune diseases, and other conditions, addressing critical unmet clinical needs.